DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
Status:
Terminated
Trial end date:
2021-03-09
Target enrollment:
Participant gender:
Summary
This research study tests an investigational drug called DS-3201b. An investigational drug is
a medication that is still being studied and has not yet been approved by the United States
Food and Drug Administration (FDA). The FDA allows DS-3201b to be used only in research. It
is not known if DS-3201b will work or not.
This study consists of two parts. The first part (Part 1) is a dose escalation that will
enroll subjects with AML or ALL that did not respond or no longer respond to previous
standard therapy. The purpose of Part 1 of this research study is to determine the highest
dose a patient can tolerate or recommended dose of DS-3201b that can be given to subjects
with AML or ALL. Once the highest tolerable dose is determined, additional subjects will be
enrolled at that dose into Part 2 of the study.